CBD seeks red-hot status – digital magazineCBD seeks red-hot status – digital magazine
Once a red-hot ingredient, cannabidiol (CBD) seeks to retake the supplement spotlight after a rocky 2020, led by new hemp-derived phytocannabinoids and other derivatives. Market saturation and regulatory uncertainty has hampered industry growth, but research on the endocannabinoid system is connecting CBD intake and various health issues, from inflammation to mood and beyond. Other minor phytocannabinoids identified for more in-depth research include cannabigerol (CBG), cannabinol (CBN) and cannabichromene (CBC).
May 13, 2021
Takeaways for your business:
• Much remains to be known about the effect of phytocannabinoids on the endocannabinoid system (ECS).
• Cannabinoids with targeted therapeutic promise could drive consumer self-care market expansion.
• Delta-8 THC is on the rise as a psychoactive alternative to THC, and the sports market is watching.
You May Also Like
The rise of ashwagandha: A case study in a growing and evolving category – articleNov 28, 2023
Ashwagandha: Roots for wellness, leaves for soil – articleNov 28, 2023
Creatine, whey protein, beta-alanine among picks in NFL-style draft at SupplySide WestDec 01, 2023
Unleash the power of ‘combos’ supplements to meet consumer demand – infographicNov 22, 2023